Drug Trial Radar · NCT00361166
Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone
Last checked: Nov 20, 2026Latest source record: Mar 22, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
400
Actual
Start
Aug 2005
Primary completion
Not stated
Study completion Mar 2007
Sponsor
- Lead sponsor
- ACADIA Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 7, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to determine whether a combination of ACP-103 (the study medication) with either haloperidol or risperidone will show antipsychotic efficacy and that it is safe and well tolerated. Further purposes of this study are to determine whether ACP-103, in combination with either haloperidol or risperidone, will enhance their antipsychotic effectiveness, demonstrate effectiveness against the negative symptoms, improve motoric tolerability, and is safe and well tolerated. This is a seven-week study (one week screening and six weeks of study medication) where a total of 400 patients who meet entrance criteria will randomly be assigned to receive one of five groups of study treatments of either low dose haloperidol plus ACP-103, low dose haloperidol plus placebo (a substance similar to a sugar pill), low dose risperidone plus ACP-103, low dose risperidone plus placebo, or high dose risperidone plus placebo. The study will begin with with a three to seven day drug-free period followed by six weeks of a stable daily dosage of study medication. Study subjects will be treated as hospital in-patients during screening and for the first 14 days of the study. Study subjects will be closely monitored throughout the study.
Conditions
- Schizophrenia
Interventions
ACP-103Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total score on the Positive and Negative Symptom Scale (PANSS).
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Cerritos, California
Site not named
Garden Grove, California
Site not named
Glendale, California
Site not named
Paramount, California
Site not named
Pico Rivera, California
Site not named
San Diego, California
Site not named
San Diego, California
Site not named
Washington D.C., District of Columbia
Site not named
St Louis, Missouri
Site not named
Austin, Texas
Site not named
Irving, Texas
Site not named
Salvador, Estado de Bahia, Brazil
Site not named
Aparecida de Goiânia, Goiás, Brazil
Site not named
Curitiba, Paraná, Brazil
Site not named
Curitiba, Paraná, Brazil
Site not named
Rio de Janeiro, Rio de Janeiro, Brazil
Site not named
São Paulo, São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.